tiprankstipranks
Trending News
More News >
Jasper Therapeutics (JSPR)
NASDAQ:JSPR
US Market
Advertisement

Jasper Therapeutics (JSPR) Stock Forecast & Price Target

Compare
1,022 Followers
See the Price Targets and Ratings of:

JSPR Analyst Ratings

Moderate Buy
7Ratings
Moderate Buy
5 Buy
2 Hold
0 Sell
Based on 7 analysts giving stock ratings to
Jasper
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

JSPR Stock 12 Month Forecast

Average Price Target

$12.60
▲(425.00% Upside)
Based on 7 Wall Street analysts offering 12 month price targets for Jasper Therapeutics in the last 3 months. The average price target is $12.60 with a high forecast of $25.00 and a low forecast of $5.00. The average price target represents a 425.00% change from the last price of $2.40.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","26":"$26","7.25":"$7.25","13.5":"$13.5","19.75":"$19.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$25.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$12.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,7.25,13.5,19.75,26],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.76,4.47076923076923,6.181538461538461,7.892307692307693,9.603076923076923,11.313846153846153,13.024615384615386,14.735384615384616,16.446153846153848,18.15692307692308,19.86769230769231,21.57846153846154,23.28923076923077,{"y":25,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.76,3.5169230769230766,4.273846153846153,5.030769230769231,5.787692307692307,6.544615384615384,7.3015384615384615,8.058461538461538,8.815384615384616,9.572307692307692,10.329230769230769,11.086153846153845,11.843076923076923,{"y":12.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.76,2.9323076923076923,3.1046153846153843,3.276923076923077,3.449230769230769,3.6215384615384614,3.793846153846154,3.966153846153846,4.138461538461538,4.310769230769231,4.483076923076923,4.655384615384616,4.827692307692308,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":21.8,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.3,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.27,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.97,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.38,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.06,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.93,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.14,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.38,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.45,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.74,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.88,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.76,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$25.00Average Price Target$12.60Lowest Price Target$5.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Citizens JMP Analyst forecast on JSPR
Citizens JMP
Citizens JMP
$12$6
Buy
150.00%
Upside
Reiterated
09/22/25
Jasper Therapeutics price target lowered to $6 from $12 at Citizens JMPJasper Therapeutics price target lowered to $6 from $12 at Citizens JMP
BTIG
$20$7
Buy
191.67%
Upside
Reiterated
09/19/25
BTIG Remains a Buy on Jasper Therapeutics (JSPR)
H.C. Wainwright Analyst forecast on JSPR
H.C. Wainwright
H.C. Wainwright
$20
Buy
733.33%
Upside
Reiterated
09/17/25
H.C. Wainwright Remains a Buy on Jasper Therapeutics (JSPR)
UBS
$29$25
Buy
941.67%
Upside
Reiterated
08/15/25
Jasper Therapeutics price target lowered to $25 from $29 at UBSJasper Therapeutics price target lowered to $25 from $29 at UBS
William Blair Analyst forecast on JSPR
William Blair
William Blair
Hold
Reiterated
08/14/25
Hold Rating on Jasper Therapeutics Amid Uncertainty in BEACON Study and Drug Development Timeline
TD Cowen Analyst forecast on JSPR
TD Cowen
TD Cowen
Buy
Reiterated
08/13/25
TD Cowen Remains a Buy on Jasper Therapeutics (JSPR)We remain Buy. 3-6 Mos Delay To Ph2b Start From Potential Mfng Issue Is Surmountable – Briquilimab continues to show robust efficacy with clean safety across CSU/CIndU, and we remain constructive on the outlook despite the recent delay from potential manufacturing issues. Mgmt continues to look into whether there was a faulty product batch used in the 240mg Q8W and 240mg + 180mg Q8W cohorts of BEACON, and results from this investigation along with data from these cohorts (which will include 10-12 new patients as well as old patients switched over to a new batch) later this year will be key to defining the path ahead for briquilimab.
RBC Capital Analyst forecast on JSPR
RBC Capital
RBC Capital
$5
Hold
108.33%
Upside
Reiterated
08/13/25
RBC Capital Sticks to Their Hold Rating for Jasper Therapeutics (JSPR)
Evercore ISI
$50$20
Buy
733.33%
Upside
Reiterated
07/08/25
Jasper Therapeutics (JSPR) Receives a Buy from Evercore ISI
Cantor Fitzgerald Analyst forecast on JSPR
Cantor Fitzgerald
Cantor Fitzgerald
Hold
Downgraded
07/07/25
Jasper Therapeutics downgraded to Neutral from Overweight at Cantor FitzgeraldJasper Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald
Oppenheimer Analyst forecast on JSPR
Oppenheimer
Oppenheimer
$65
Buy
2608.33%
Upside
Reiterated
06/16/25
Oppenheimer Remains a Buy on Jasper Therapeutics (JSPR)
Wells Fargo Analyst forecast on JSPR
Wells Fargo
Wells Fargo
$80
Buy
3233.33%
Upside
Reiterated
03/02/25
Promising Outlook for Jasper Therapeutics: Buy Rating Amidst Potential Upside and Strategic Developments
Barclays Analyst forecast on JSPR
Barclays
Barclays
$63
Buy
2525.00%
Upside
Initiated
02/27/25
Promising Outlook for Jasper Therapeutics: Buy Rating Backed by Briquilimab's Clinical Progress and Financial Stability
Capital One Financial Analyst forecast on JSPR
Capital One Financial
Capital One Financial
$55
Buy
2191.67%
Upside
Assigned
10/23/24
Buy Rating on Jasper Therapeutics Driven by Promising Clinical Developments and Strategic Advancements
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Citizens JMP Analyst forecast on JSPR
Citizens JMP
Citizens JMP
$12$6
Buy
150.00%
Upside
Reiterated
09/22/25
Jasper Therapeutics price target lowered to $6 from $12 at Citizens JMPJasper Therapeutics price target lowered to $6 from $12 at Citizens JMP
BTIG
$20$7
Buy
191.67%
Upside
Reiterated
09/19/25
BTIG Remains a Buy on Jasper Therapeutics (JSPR)
H.C. Wainwright Analyst forecast on JSPR
H.C. Wainwright
H.C. Wainwright
$20
Buy
733.33%
Upside
Reiterated
09/17/25
H.C. Wainwright Remains a Buy on Jasper Therapeutics (JSPR)
UBS
$29$25
Buy
941.67%
Upside
Reiterated
08/15/25
Jasper Therapeutics price target lowered to $25 from $29 at UBSJasper Therapeutics price target lowered to $25 from $29 at UBS
William Blair Analyst forecast on JSPR
William Blair
William Blair
Hold
Reiterated
08/14/25
Hold Rating on Jasper Therapeutics Amid Uncertainty in BEACON Study and Drug Development Timeline
TD Cowen Analyst forecast on JSPR
TD Cowen
TD Cowen
Buy
Reiterated
08/13/25
TD Cowen Remains a Buy on Jasper Therapeutics (JSPR)We remain Buy. 3-6 Mos Delay To Ph2b Start From Potential Mfng Issue Is Surmountable – Briquilimab continues to show robust efficacy with clean safety across CSU/CIndU, and we remain constructive on the outlook despite the recent delay from potential manufacturing issues. Mgmt continues to look into whether there was a faulty product batch used in the 240mg Q8W and 240mg + 180mg Q8W cohorts of BEACON, and results from this investigation along with data from these cohorts (which will include 10-12 new patients as well as old patients switched over to a new batch) later this year will be key to defining the path ahead for briquilimab.
RBC Capital Analyst forecast on JSPR
RBC Capital
RBC Capital
$5
Hold
108.33%
Upside
Reiterated
08/13/25
RBC Capital Sticks to Their Hold Rating for Jasper Therapeutics (JSPR)
Evercore ISI
$50$20
Buy
733.33%
Upside
Reiterated
07/08/25
Jasper Therapeutics (JSPR) Receives a Buy from Evercore ISI
Cantor Fitzgerald Analyst forecast on JSPR
Cantor Fitzgerald
Cantor Fitzgerald
Hold
Downgraded
07/07/25
Jasper Therapeutics downgraded to Neutral from Overweight at Cantor FitzgeraldJasper Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald
Oppenheimer Analyst forecast on JSPR
Oppenheimer
Oppenheimer
$65
Buy
2608.33%
Upside
Reiterated
06/16/25
Oppenheimer Remains a Buy on Jasper Therapeutics (JSPR)
Wells Fargo Analyst forecast on JSPR
Wells Fargo
Wells Fargo
$80
Buy
3233.33%
Upside
Reiterated
03/02/25
Promising Outlook for Jasper Therapeutics: Buy Rating Amidst Potential Upside and Strategic Developments
Barclays Analyst forecast on JSPR
Barclays
Barclays
$63
Buy
2525.00%
Upside
Initiated
02/27/25
Promising Outlook for Jasper Therapeutics: Buy Rating Backed by Briquilimab's Clinical Progress and Financial Stability
Capital One Financial Analyst forecast on JSPR
Capital One Financial
Capital One Financial
$55
Buy
2191.67%
Upside
Assigned
10/23/24
Buy Rating on Jasper Therapeutics Driven by Promising Clinical Developments and Strategic Advancements
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Jasper Therapeutics

1 Month
xxx
Success Rate
6/10 ratings generated profit
60%
Average Return
+6.30%
assigned a xxx
rating 12 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 60.00% of your transactions generating a profit, with an average return of +6.30% per trade.
3 Months
xxx
Success Rate
6/15 ratings generated profit
40%
Average Return
+2.83%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 40.00% of your transactions generating a profit, with an average return of +2.83% per trade.
1 Year
Jay OlsonOppenheimer
Success Rate
2/15 ratings generated profit
13%
Average Return
-44.53%
reiterated a buy rating 4 months ago
Copying Jay Olson's trades and holding each position for 1 Year would result in 13.33% of your transactions generating a profit, with an average return of -44.53% per trade.
2 Years
xxx
Success Rate
1/12 ratings generated profit
8%
Average Return
-57.47%
reiterated a xxx
rating 24 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 8.33% of your transactions generating a profit, with an average return of -57.47% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

JSPR Analyst Recommendation Trends

Rating
May 25
Jun 25
Jul 25
Aug 25
Sep 25
Strong Buy
9
9
15
14
13
Buy
5
3
4
3
2
Hold
0
0
4
6
7
Sell
1
1
0
0
0
Strong Sell
0
0
0
0
0
total
15
13
23
23
22
In the current month, JSPR has received 15 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings. JSPR average Analyst price target in the past 3 months is 12.60.
Each month's total comprises the sum of three months' worth of ratings.

JSPR Financial Forecast

JSPR Earnings Forecast

Next quarter’s earnings estimate for JSPR is -$1.19 with a range of -$1.92 to -$0.75. The previous quarter’s EPS was -$1.74. JSPR beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year JSPR has Preformed in-line its overall industry.
Next quarter’s earnings estimate for JSPR is -$1.19 with a range of -$1.92 to -$0.75. The previous quarter’s EPS was -$1.74. JSPR beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year JSPR has Preformed in-line its overall industry.
No data currently available

JSPR Sales Forecast

Next quarter’s sales forecast for JSPR is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. JSPR beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year JSPR has Preformed in-line its overall industry.
Next quarter’s sales forecast for JSPR is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. JSPR beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year JSPR has Preformed in-line its overall industry.

JSPR Stock Forecast FAQ

What is JSPR’s average 12-month price target, according to analysts?
Based on analyst ratings, Jasper Therapeutics’s 12-month average price target is 12.60.
    What is JSPR’s upside potential, based on the analysts’ average price target?
    Jasper Therapeutics has 425.00% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is JSPR a Buy, Sell or Hold?
          Jasper Therapeutics has a consensus rating of Moderate Buy which is based on 5 buy ratings, 2 hold ratings and 0 sell ratings.
            What is Jasper Therapeutics’s price target?
            The average price target for Jasper Therapeutics is 12.60. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $25.00 ,the lowest forecast is $5.00. The average price target represents 425.00% Increase from the current price of $2.4.
              What do analysts say about Jasper Therapeutics?
              Jasper Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 7 Wall Streets Analysts.
                How can I buy shares of JSPR?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis